Compare PUK & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PUK | ONC |
|---|---|---|
| Founded | 1848 | 2010 |
| Country | Hong Kong | Switzerland |
| Employees | 15338 | 12000 |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.7B | 31.4B |
| IPO Year | N/A | N/A |
| Metric | PUK | ONC |
|---|---|---|
| Price | $31.19 | $308.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $385.10 |
| AVG Volume (30 Days) | ★ 645.6K | 201.9K |
| Earning Date | 03-26-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $723.76 |
| Revenue Next Year | $8.92 | $15.04 |
| P/E Ratio | ★ $23.76 | $614.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.14 | $235.35 |
| 52 Week High | $34.03 | $385.22 |
| Indicator | PUK | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 53.74 | 52.82 |
| Support Level | $31.15 | $302.26 |
| Resistance Level | $31.38 | $316.25 |
| Average True Range (ATR) | 0.53 | 8.47 |
| MACD | -0.05 | -0.61 |
| Stochastic Oscillator | 60.24 | 57.66 |
Originally established in 1848 as the Prudential Mutual Assurance, Investment, and Loan Association, Prudential has changed a lot since. Set up to sell life insurance and loans to the middle class, the company subsequently diversified into Europe and then North America with the purchase of Jackson National Life around 1985. During its time as owner of Jackson, Prudential focused on building a simple chassis-style product portfolio that allowed customers to choose from a variety of add-ons. The company also became renowned for its focus on building the internal capabilities required to support its strong product offerings, including compelling technology and a large well-trained wholesale salesforce.
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.